Airbus Cuts Jet Production Target Amid Pratt & Whitney Engine Shortages, Q4 Profit Jumps 17% 
BHP Group Half-Year Profit Surges as Copper Overtakes Iron Ore on AI-Driven Demand 
Medical Groups Sue FTC Over Gender-Affirming Care Investigations Amid Trump Policy Dispute 
Santos Wins Court Case Over Net Zero and Sustainability Claims 
Ireland’s Data Protection Commission Launches GDPR Investigation Into X’s AI Chatbot Grok 
Microsoft Responds to ICE Surveillance Concerns Amid Azure Cloud Expansion 
Goldman Sachs Reportedly Drops Diversity Criteria From Board Candidate Evaluations 
Luxury Stocks Face Volatility as AI Market Swings and Hedge Fund Bets Rattle LVMH and Kering 
Waymo Clarifies Role of Remote Workers Amid U.S. Robotaxi Safety Scrutiny 
Vietnam Airlines, Vietjet, and Sun PhuQuoc Airways Sign Major Boeing Aircraft Deals Amid U.S.–Vietnam Trade Talks 
Federal Court Fines Mobil Oil Australia A$16 Million for Misleading Fuel Claims 
Reese’s Peanut Butter Cup Recipe Debate: Hershey Responds as Cocoa Prices Shift 
Anderson Cooper to Exit CBS News’ 60 Minutes After Nearly 20 Years 
OpenAI Nears $100 Billion Funding Round at $850 Billion Valuation: Bloomberg Report 
NAB Shares Hit Record High as First-Quarter Cash Earnings Jump 16% 
Boeing Secures 50 737 MAX Jet Order from Vietnam Airlines Amid Expanding Global Demand 
WEST LAFAYETTE, Ind., May 02, 2018 -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced that the company will host a conference call on Wednesday, May 9th, at 8:30 a.m. EDT to discuss its first quarter financial results and provide an operational update.
Investors and the general public are invited to listen to a live webcast of the call, which can be accessed in the Investors & News section of the Company’s website at www.endocyte.com or by dialing (877) 845-0711 (U.S./Canada) or (760) 298-5081 (International).
The webcast will be recorded and available on the Company’s website for 90 days following the call.
Website Information
Endocyte routinely posts important information for investors on its website, www.endocyte.com, in the “Investors & News” section. Endocyte uses this website as a means of disclosing material information in compliance with its disclosure obligations under Regulation FD. Accordingly, investors should monitor the “Investors & News” section of Endocyte’s website, in addition to following its press releases, SEC filings, public conference calls, presentations and webcasts. The information contained on, or that may be accessed through, Endocyte’s website is not incorporated by reference into, and is not a part of, this document.
About Endocyte
Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the personalized treatment of cancer. The company's drug conjugation technology targets therapeutics and companion imaging agents specifically to the site of diseased cells. Endocyte's lead program is a prostate specific membrane antigen (PSMA)-targeted radioligand therapy, 177Lu-PSMA-617, entering phase 3 for metastatic castration resistant prostate cancer (mCRPC). Endocyte is also advancing its adaptor-controlled CAR T-cell therapy into the clinic in 2018, where it will be studied in osteosarcoma. For additional information, please visit Endocyte's website at www.endocyte.com.
Investor Contact:
Stephanie Ascher, Stern Investor Relations, Inc., (212) 362-1200, [email protected]
